Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

th R/R MM was initiated in the third quarter of 2013. The Phase I portion of this study is a dose escalation study designed to assess the safety and recommended Phase IIb dose of IMBRUVICA and carfilzomib. The Phase IIb portion will be a randomized, double-blind, placebo controlled study to evaluate the efficacy of IMBRUVICA and carfilzomib versus carfilzomib and placebo. The primary endpoint of the Phase IIb portion of the study is progression-free survival. The enrollment target of this study is 176 patients.

Conference CallThe Company will hold a conference call today at 4:30 p.m. ET. To participate, please dial 1-877-303-7908 (domestic callers) and 1-678-373-0875 (international callers). To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast and conference call will be available for 30 days on the Investor Relations section of the Company's Web site at http://www.pharmacyclics.com.

About IMBRUVICAIMBRUVICA is indicated for the treatment of patients with mantle cell lymphoma or chronic lymphocytic leukemia who have received at least one prior therapy, and for patients with chronic lymphocytic leukemia with deletion of 17p who are either treatment naïve or previously treated. Accelerated approval was granted for the MCL indication and is based on overall response rate. Improvements in survival or disease-related symptoms have not been established. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.

IMBRUVICA is a new, first-in-class, oral therapy that inhibits an enzyme called Bruton tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival and spread of malignant B-cells. IMBRUVICA bloc
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
3. WuXi PharmaTech to Partner with Pharmacyclics
4. Pharmacyclics Reports Third Quarter 2013 Results
5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
6. Pharmacyclics Reports Second Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
8. Pharmacyclics Reports First Quarter 2013 Results
9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 DePuy Synthes CMF* today ... the first commercially available biosynthesized dural replacement derived from ... a part of the DePuy Synthes Companies of Johnson ... membrane that covers and protects the brain and spinal ... allow surgeons to access the brain. A dural graft, ...
(Date:5/4/2015)... May 4, 2015 Thirty-six million Americans suffer ... During May – National Hearing Month – more than ... missing out on the sounds of spring, like birds ... To ensure that you won,t be among those ... world, Oticon, Inc. offers practical advice: Take ...
(Date:5/4/2015)... MUNDELEIN, Ill. , May 4, 2015 ... , with live video and product demonstrations at the ... Radiology imaging equipment such as Kodak and Fuji Cr,s, ... be auctioned at the first event. Various imaging equipment ... www.RadiologyAuction.com . After years of buying ...
Breaking Medicine Technology:DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3It's Better Hearing Month 2RadiologyAuction Announces Event Starting On May 5th 2
(Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
(Date:5/4/2015)... May 04, 2015 Johnson & Wales University ... engineering and science academic center on Wednesday, April 22. , ... for land made available by the re-alignment of Interstate-195. JWU’s ... of Friendship and Chestnut streets in Providence, is scheduled to ... a parcel of land the university purchased in 2012. , ...
(Date:5/4/2015)... The opportunity for children to dream of ... motivating forces behind The Fairy Godmother Next Door, a new ... L. Stark. , The inspiration for the enchanting story of ... from Stark’s desire to be a fairy godmother. , “My ... to my neighbors’ children since they were born. We discuss ...
(Date:5/4/2015)... 04, 2015 Now in its seventh ... leaders who have made outstanding contributions to the company, ... both in acute and post-acute care settings. The five ... Provider of the Year, Advanced Practice Clinician of the ... of the Year. Recipients are selected by IPC’s senior ...
(Date:5/4/2015)... VA (PRWEB) May 04, 2015 Ticket Down ... at the John Paul Jones Arena in Charlottesville, VA. ... the history of the music business and this beloved performer ... Paul McCartney, the former member of two legendary groups: Wings ... in the music business since 2013 on the “Out There” ...
Breaking Medicine News(10 mins):Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2
... from shelves as FDA advises consumers not to eat ... continues , , TUESDAY, Jan. 20 (HealthDay News) -- Peanut ... as more grocery chains and specialty companies joined a ... recalls follows a U.S. Food and Drug Administration warning ...
... 20 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink Sheets: ... in the People,s Republic of China (,PRC,),today announced ... as its new,independent auditor, effective January 9, 2009. ... ("Schwartz"), which was dismissed on the same,day. , ...
... $63.7 Billion increased 4.3%; Full-Year EPS was $4.572008 Fourth-Quarter ... Special Items, 2008 Full-Year EPS was $4.55, an increase ... of 6.8%* , NEW BRUNSWICK, N.J., Jan. 20 ... 2008 of $63.7 billion, an increase of 4.3% over ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) today announced the tax treatment of its 2008 distributions as follows:, ... CUSIP: 09063H107, ... Total ... Payable Distribution Allocable Ordinary, Date ...
... inspection specials during National Radon Awareness Month. , ... Cleveland, OH (PRWeb) ... to the Environmental Protection Agency (EPA), nearly 1 out of every 15 ... causing thousands of lung cancer deaths in the U.S. each year. ...
... 20 Abbott ( NYSE: ABT ... analytical research laboratory,in Singapore,s Biopolis research park. This ... in Southeast Asia, will conduct,stability studies, including studies ... global regulatory requirements for new,pharmaceutical products. The ...
Cached Medicine News:Health News:More Peanut Butter Products Join Recall List 2Health News:More Peanut Butter Products Join Recall List 3Health News:More Peanut Butter Products Join Recall List 4Health News:Renhuang Pharmaceuticals, Inc. Engages New Independent Auditor 2Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 2Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 3Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 4Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 5Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 6Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 7Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 8Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 9Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 10Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 11Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 12Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 13Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 14Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 15Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 16Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 17Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 18Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 19Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 20Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 21Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 22Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 23Health News:Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results 24Health News:BioMed Realty Trust Announces Tax Treatment of 2008 Distributions 2Health News:BioMed Realty Trust Announces Tax Treatment of 2008 Distributions 3Health News:Saving Lives One Radon Inspection at a Time 2Health News:Abbott Opens New Pharmaceutical Research Laboratory in Singapore 2Health News:Abbott Opens New Pharmaceutical Research Laboratory in Singapore 3
... provide outstanding insertion performance, with ... high kink resistance and minimal ... sheath cannula provides optimal strength ... an extra strong dilator to ...
6.5mm diameter handpiece; 75mm handle with grooves for grip; Standard male luer taper fits most cannula hub and female luer taper....
Hook Shaped Tip , Curved to the Left; with 30 cm long silicone tubing with connector; overall length 40mm; stainless steel...
... The Cordis biopsy forceps are designed for ... Biopsy Forceps consist of a 3-pull ring handle, ... The flexible thumb ring rotates to accommodate any ... cutting jaws closed. The jaws are opened by ...
Medicine Products: